Top Life Science Tool Companies

The primary driver of the Global Life Science Tools Market is the rapid advancement in genomics and proteomics research. The increasing focus on precision medicine and molecular diagnostics has accelerated the demand for high-throughput sequencing, bioinformatics tools, and analytical instruments. This surge in genomic data generation creates a need for advanced tools to analyse and interpret complex biological information, directly fuelling market growth. As researchers aim to uncover disease mechanisms and develop targeted therapies, the reliance on innovative life science tools continues to expand, establishing genomics research as a central catalyst for the market’s sustained expansion.

Industry Overview

According to SkyQuest Technology “Global Life Science Tool Market” By Product Type (Instruments, Consumables), By Technology (Genomics Technology, Proteomics Technology), By Application, By End User, By Region - Industry Forecast 2025-2032,” Global life science tool market is projected to grow at a CAGR of over 10.81% by 2032, on account of urgent need for automating quantified data. A key factor influencing the Global Life Science Tools Market is the rising investment in pharmaceutical and biotechnology R&D. Growing efforts to develop novel therapeutics, vaccines, and biologics have intensified the demand for sophisticated analytical instruments, reagents, and cell culture technologies.

Top 10 Global Life Science Tool Companies

1. Thermo Fisher Scientific

Bluebird Bio is a global biotechnology company focused on developing innovative gene and cell therapies to treat severe genetic diseases and cancer. Founded in 1992 and headquartered in Cambridge, Massachusetts, the company has established itself as a leader in gene editing and CAR T-cell therapy. Its core offerings include gene therapies for conditions such as sickle cell disease and cerebral adrenoleukodystrophy, along with CAR T-cell therapies targeting hematologic malignancies. Bluebird Bio continues to expand its pipeline through research collaborations and strategic partnerships, driving innovation in advanced therapeutics.

2. Agilent Technologies

Medigene AG is a Germany-based biotechnology company specializing in the development of innovative T cell-based immunotherapies for cancer treatment. Founded in 1997 and headquartered in Martinsried, the company focuses on TCR-T cell therapies, co-stimulatory switch proteins, and immuno-oncology platforms. Medigene conducts extensive clinical trials targeting both solid tumors and hematologic malignancies, aiming to deliver safe and effective treatments. Through strategic collaborations and partnerships with academic and industry leaders, Medigene AG continues to advance its pipeline, solidifying its position as a pioneering force in precision immunotherapy and cellular therapy innovation.

3. Bio-Rad Laboratories

Atara Biotherapeutics is a global biopharmaceutical company focused on developing allogeneic T-cell immunotherapies for cancer and autoimmune diseases. Founded in 2012 and headquartered in South San Francisco, California, the company specializes in off-the-shelf EBV-targeted T-cell therapies and innovative pipeline programs. Its core offerings include treatments for hematologic malignancies, solid tumors, and autoimmune conditions. Atara Biotherapeutics advances its research through clinical trials, strategic collaborations, and manufacturing innovations, aiming to provide safe, effective, and scalable therapies. The company continues to expand its presence in the cellular therapy and immuno-oncology landscape.

4. Danaher Corporation

Gilead Sciences is a global biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for life-threatening diseases. Founded in 1987 and headquartered in Foster City, California, Gilead has grown into a leader in antiviral treatments, oncology, and cellular therapies, including CAR T-cell research. Its core offerings span HIV, hepatitis, and oncology treatments, with ongoing advancements in gene and cell therapy pipelines. Through strategic acquisitions, research collaborations, and clinical trials, Gilead continues to expand its impact on global healthcare, driving innovation and delivering transformative therapies to patients worldwide.

5. Illumina, Inc.

Celyad Oncology is a global biopharmaceutical company focused on developing innovative allogeneic CAR T-cell therapies for cancer treatment. Founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, the company specializes in engineered T-cell therapies designed to target hematologic malignancies and solid tumors. Its core offerings include advanced CAR T-cell platforms and proprietary technology for enhancing safety and efficacy. Celyad Oncology advances its pipeline through rigorous clinical trials, strategic collaborations, and manufacturing innovations, aiming to deliver accessible, effective, and next-generation immunotherapies that transform the standard of care in oncology worldwide.

6. QIAGEN N.V.

Juno Therapeutics, a subsidiary of Bristol-Myers Squibb, is a global biopharmaceutical company focused on developing innovative CAR T-cell therapies for blood cancers. Founded in 2013 and headquartered in Seattle, Washington, the company specializes in engineered T-cell therapies designed to provide targeted, durable responses in hematologic malignancies. Its core offerings include CAR T-cell platforms, clinical development programs, and pipeline therapies for leukemia and lymphoma. Juno Therapeutics advances its mission through strategic partnerships, research collaborations, and clinical trials, driving innovation in cellular immunotherapy and improving outcomes for patients worldwide.

7. Waters Corporation

Legend Biotech is a global biopharmaceutical company dedicated to developing innovative CAR T-cell therapies for cancer treatment. Founded in 2014 and headquartered in Nanjing, China, the company focuses on targeted therapies for multiple myeloma and other hematologic malignancies. Its core offerings include advanced CAR T-cell platforms, clinical development programs, and a robust research pipeline. Legend Biotech advances its mission through strategic collaborations, global clinical trials, and manufacturing innovations, aiming to provide safe, effective, and accessible cell therapies that transform cancer treatment and improve patient outcomes worldwide.

8. PerkinElmer, Inc.

Autolus Therapeutics is a global biopharmaceutical company focused on developing next-generation autologous T-cell therapies for cancer treatment. Founded in 2014 and headquartered in London, UK, the company specializes in engineered T-cell platforms designed to provide targeted, durable responses in hematologic malignancies and solid tumors. Its core offerings include CAR T-cell therapies, cell programming technologies, and a robust clinical development pipeline. Autolus advances its mission through strategic collaborations, innovative manufacturing processes, and global clinical trials, aiming to deliver safe, effective, and accessible cellular immunotherapies that improve patient outcomes worldwide.

9. Bruker Corporation

Kite Pharma, a subsidiary of Gilead Sciences, is a global biopharmaceutical company specializing in the development of innovative CAR T-cell therapies for cancer treatment. Founded in 2009 and headquartered in Santa Monica, California, the company focuses on engineered T-cell platforms designed to treat hematologic malignancies and solid tumors. Its core offerings include CAR T-cell therapies, clinical development programs, and advanced manufacturing capabilities. Kite Pharma drives innovation through global clinical trials, strategic collaborations, and research initiatives, aiming to deliver safe, effective, and accessible cellular immunotherapies that transform cancer care worldwide.

10. Shimadzu Corporation

Poseida Therapeutics is a global biopharmaceutical company focused on developing innovative allogeneic CAR T-cell therapies and gene therapies for cancer and other serious diseases. Founded in 2014 and headquartered in San Diego, California, the company specializes in engineered T-cell platforms designed to provide targeted, durable, and scalable treatment options. Its core offerings include CAR T-cell therapies, gene editing technologies, clinical development programs, and manufacturing innovations. Poseida Therapeutics advances its mission through strategic collaborations, global clinical trials, and research initiatives, aiming to deliver safe, effective, and accessible cellular immunotherapies worldwide.

Other Leading Global Life Science Tool Companies

• Beckman Coulter
• Sartorius AG
• Promega Corporation
• New England Biolabs
• Lonza Group AG
• Bio-Techne Corporation
• Cytiva
• Takara Bio Inc.
• Hamilton Company
• Oxford Instruments plc

Conclusion

The global life science tools market is experiencing strong and sustained growth, propelled by rapid innovations in genomics, proteomics, and molecular diagnostics. As precision medicine and data-driven research gain momentum, demand for advanced analytical instruments, sequencing technologies, and bioinformatics solutions continues to rise. Simultaneously, increasing investments in pharmaceutical and biotechnology R&D are expanding the scope of applications, from drug discovery to clinical diagnostics. Major industry players are driving innovation through strategic partnerships, technological upgrades, and global expansion. Together, these forces are fostering a dynamic, competitive market ecosystem that underpins the advancement of modern biomedical research and personalized healthcare.